A new painkiller nanomedicine to bypass the blood-brain barrier and the use of morphine

Jiao Feng,Sinda Lepetre-Mouelhi,Anne Gautier,Simona Mura,Catherine Cailleau,François Coudore,Michel Hamon,Patrick Couvreur

DOI: https://doi.org/10.1126/sciadv.aau5148

IF: 13.6

2019-02-01

Science Advances

Abstract:A novel painkiller nanomedicine triggers the specific delivery of enkephalin neuropeptide into inflamed tissues.

multidisciplinary sciences

What problem does this paper attempt to address?

Mesoporous Silica Particles As a Multifunctional Delivery System for Pain Relief in Experimental Neuropathy.

Junran Xie,Dongju Xiao,Jinning Zhao,Nianqiang Hu,Qi Bao,Li Jiang,Lina Yu

DOI: https://doi.org/10.1002/adhm.201500996

2016-01-01

Abstract:The long‐term use of potent analgesics is often needed to treat chronic pain. However, it has been greatly hindered by their side effects such as addiction and withdrawal reactions. The study seeks to circumvent these drawbacks by taking advantage of a multifunctional delivery system based on nanoparticles to target on pathological neuroinflammation. A drug delivery system is designed and generated using mesoporous silica nanoparticles (MSNs) that are loaded with Δ9‐THC (Δ9‐tetrahydrocannabinol, a cannabinoid) and ARA290 (an erythropoietin‐derived polypeptide), both of which possess analgesic and anti‐inflammatory functions. The actions of such THC‐MSN‐ARA290 nanocomplexes depend on the enhanced permeability and retention of THC through nanosized carriers, and a redox‐sensitive release of conjugated ARA290 peptide into the local inflammatory milieu. The biosafety and anti‐inflammatory effects of the nanocomplexes are first evaluated in primary microglia in vitro, and further in a mouse model of chronic constriction injury. It is found that the nanocomplexes attenuate in vitro and in vivo inflammation, and achieve a sustained relief of neuropathic pain in injured animals induced by both thermal hyperalgesia and mechanical allodynia. Thus, a nanoparticle‐based carrier system can be useful for the amelioration of chronic neuropathic pain through combinatorial drug delivery.
Design, Synthesis, and Biological Evaluation of the Third Generation 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan (NAP) Derivatives As Μ/κ Opioid Receptor Dual Selective Ligands.

Yi Zheng,Samuel Obeng,Huiqun Wang,Abdulmajeed M. Jali,Bharath Peddibhotla,Dwight A. Williams,Chuanchun Zou,David L. Stevens,William L. Dewey,Hamid I. Akbarali,Dana E. Selley,Yan Zhang

DOI: https://doi.org/10.1021/acs.jmedchem.8b01158

IF: 8.039

2019-01-01

Journal of Medicinal Chemistry

Abstract:μ opioid receptor (MOR) agonists have been widely applied for treating moderate to severe pain. However, numerous adverse effects have been associated with their application, including opioid-induced constipation (OIC), respiratory depression, and addiction. On the basis of previous work in our laboratory, NAP, a 6β- N-4'-pyridyl substituted naltrexamine derivative, was identified as a peripheral MOR antagonist that may be used to treat OIC. To further explore its structure-activity relationship, a new series of NAP derivatives were designed, synthesized, and biologically evaluated. Among these derivatives, NFP and NYP significantly antagonized the antinociception effect of morphine. Whereas NAP acted mainly peripherally, its derivatives NFP and NYP actually can act centrally. Furthermore, NFP produced significantly lesser withdrawal symptoms than naloxone at similar doses. These results suggest that NFP has the potential to be a lead compound to treat opioid abuse and addiction.
A Synthetic Peptide Exerts Nontolerance-Forming Antihyperalgesic and Antidepressant Effects in Mice

Yongjiang Wu,Xiaofei Song,YanZhe Ji,Gang Chen,Long Zhao

DOI: https://doi.org/10.1016/j.neurot.2024.e00377

IF: 6.088

2024-01-01

Neurotherapeutics

Abstract:Chronic pain is a prevalent and persistent ailment that affects individuals worldwide. Conventional medications employed in the treatment of chronic pain typically demonstrate limited analgesic effectiveness and frequently give rise to debilitating side effects, such as tolerance and addiction, thereby diminishing patient compliance with medication. Consequently, there is an urgent need for the development of efficacious novel analgesics and innovative methodologies to address chronic pain. Recently, a growing body of evidence has suggested that multireceptor ligands targeting opioid receptors (ORs) are favorable for improving analgesic efficacy, decreasing the risk of adverse effects, and occasionally yielding additional advantages. In this study, the intrathecal injection of a recently developed peptide (VYWEMEDKN) at nanomolar concentrations decreased pain sensitivity in naïve mice and effectively reduced pain-related behaviors in nociceptive pain model mice with minimal opioid-related side effects. Importantly, the compound exerted significant rapid-acting antidepressant effects in both the forced swim test and tail suspension test. It is possible that the rapid antihyperalgesic and antidepressant effects of the peptide are mediated through the OR pathway. Overall, this peptide could both effectively provide pain relief and alleviate depression with fewer side effects, suggesting that it is a potential agent for chronic pain and depression comorbidities from the perspective of pharmaceutical development.
Pain relief devoid of opioid side effects following central action of a silylated neurotensin analog

Pascal Tétreault,Élie Besserer-Offroy,Rebecca L Brouillette,Adeline René,Alexandre Murza,Roberto Fanelli,Karyn Kirby,Alexandre J Parent,Isabelle Dubuc,Nicolas Beaudet,Jérôme Côté,Jean-Michel Longpré,Jean Martinez,Florine Cavelier,Philippe Sarret

DOI: https://doi.org/10.1016/j.ejphar.2020.173174

2020-09-05

Abstract:Neurotensin (NT) exerts naloxone-insensitive antinociceptive action through its binding to both NTS1 and NTS2 receptors and NT analogs provide stronger pain relief than morphine on a molecular basis. Here, we examined the analgesic/adverse effect profile of a new NT(8-13) derivative denoted JMV2009, in which the Pro10 residue was substituted by a silicon-containing unnatural amino acid silaproline. We first report the synthesis and in vitro characterization (receptor-binding affinity, functional activity and stability) of JMV2009. We next examined its analgesic activity in a battery of acute, tonic and chronic pain models. We finally evaluated its ability to induce adverse effects associated with chronic opioid use, such as constipation and analgesic tolerance or related to NTS1 activation, like hypothermia. In in vitro assays, JMV2009 exhibited high binding affinity for both NTS1 and NTS2, improved proteolytic resistance as well as agonistic activities similar to NT, inducing sustained activation of p42/p44 MAPK and receptor internalization. Intrathecal injection of JMV2009 produced dose-dependent antinociceptive responses in the tail-flick test and almost completely abolished the nociceptive-related behaviors induced by chemical somatic and visceral noxious stimuli. Likewise, increasing doses of JMV2009 significantly reduced tactile allodynia and weight bearing deficits in nerve-injured rats. Importantly, repeated agonist treatment did not result in the development of analgesic tolerance. Furthermore, JMV2009 did not cause constipation and was ineffective in inducing hypothermia. These findings suggest that NT drugs can act as an effective opioid-free medication for the management of pain or can serve as adjuvant analgesics to reduce the opioid adverse effects.
Intrinsic anti-inflammatory nanomedicines for enhanced pain management

Bin Qiao,Jiaqian Yao,Yu'ang Fan,Na Zhang,Miao Feng,Jiaju Zhao,Xinye Song,Yong Luan,Bowen Zhuang,Nan Zhang,Xiaoyan Xie,Ming Xu

DOI: https://doi.org/10.3389/fbioe.2024.1514245

IF: 5.7

2024-12-17

Frontiers in Bioengineering and Biotechnology

Abstract:Introduction: Effective postoperative pain management remains a significant challenge due to the severe side effects of opioids and the limitations of existing analgesic delivery systems. Inflammation plays a critical role in pain exacerbation, highlighting the need for therapies that combine analgesic effects with intrinsic anti-inflammatory properties. Methods: Herein, we develop an intrinsic anti-inflammatory nanomedicine designed to enhance pain management by integrating controlled anesthetic release with inherent anti-inflammatory activity. Our nanoplatform utilizes dendritic mesoporous silica nanoparticles (MSNs) loaded with levobupivacaine and coated with Rg3-based liposomes derived from ginsenoside Rg3, termed LMSN-bupi. Results: The MSNs enable sustained and controlled release of the local anesthetic, while the Rg3-liposome coating provides intrinsic anti-inflammatory effects by inhibiting macrophage activation. In animal models, LMSN-bupi demonstrates significantly prolonged analgesic effects and attenuated inflammatory responses compared to traditional liposome-decorated nanoparticles (TMSN-bupi) (n = 5). Discussion: These findings underscore the potential of intrinsic anti-inflammatory nanomedicines in enhancing pain management, offering a promising strategy to overcome the limitations of current therapies and improve patient outcomes in postoperative care.

multidisciplinary sciences
Analgesic Nanomedicines for the Treatment of Chronic Pain

Hao Liu,Hongjun Zhuang,Ya Wang,Yuen Yee Cheng,Feixiang Chen,Jian Chen,Xinglei Song,Run Zhang,Yanyan Liu,Wenbo Bu

DOI: https://doi.org/10.1002/bmm2.12049

2024-01-01

Abstract:Abstract Chronic pain is a major cause of suffering that often accompanies diseases and therapies, affecting approximately 20% of individuals at some point in their lives. However, current treatment modalities, such as anesthetic and antipyretic analgesics, have limitations in terms of efficacy and side effects. Nanomedical technology offers a promising avenue to overcome these challenges and introduce new therapeutic mechanisms. This article reviews the recent research on nanomedicine analgesics, integrating analyses of neuroplasticity changes in neurons and pathways related to the transition from acute to chronic pain. Furthermore, it explores potential future strategies using nanomaterials, aiming to provide a roadmap for new analgesic development and improved clinical pain management. By leveraging nanotechnology, these approaches hold the potential to revolutionize pain treatment by delivering targeted and effective relief while minimizing side effects.
Building a better analgesic: multifunctional compounds that address injury-induced pathology to enhance analgesic efficacy while eliminating unwanted side effects

T M Largent-Milnes,S W Brookshire,D P Skinner Jr,K E Hanlon,D Giuvelis,T Yamamoto,P Davis,C R Campos,P Nair,S Deekonda,E J Bilsky,F Porreca,V J Hruby,T W Vanderah

DOI: https://doi.org/10.1124/jpet.113.205245

Abstract:The most highly abused prescription drugs are opioids used for the treatment of pain. Physician-reported drug-seeking behavior has resulted in a significant health concern among doctors trying to adequately treat pain while limiting the misuse or diversion of pain medications. In addition to abuse liability, opioid use is associated with unwanted side effects that complicate pain management, including opioid-induced emesis and constipation. This has resulted in restricting long-term doses of opioids and inadequate treatment of both acute and chronic debilitating pain, demonstrating a compelling need for novel analgesics. Recent reports indicate that adaptations in endogenous substance P/neurokinin-1 receptor (NK1) are induced by chronic pain and sustained opioid exposure, and these changes may contribute to processes responsible for opioid abuse liability, emesis, and analgesic tolerance. Here, we describe a multifunctional mu-/delta-opioid agonist/NK1 antagonist compound [Tyr-d-Ala-Gly-Phe-Met-Pro-Leu-Trp-NH-Bn(CF3)2 (TY027)] that has a preclinical profile of excellent antinociceptive efficacy, low abuse liability, and no opioid-related emesis or constipation. In rodent models of acute and neuropathic pain, TY027 demonstrates analgesic efficacy following central or systemic administration with a plasma half-life of more than 4 hours and central nervous system penetration. These data demonstrate that an innovative opioid designed to contest the pathology created by chronic pain and sustained opioids results in antinociceptive efficacy in rodent models, with significantly fewer side effects than morphine. Such rationally designed, multitargeted compounds are a promising therapeutic approach in treating patients who suffer from acute and chronic pain.
TET1-Lipid Nanoparticle Encapsulating Morphine for Specific Targeting of Peripheral Nerve for Pain Alleviation

Hongmei Yang,Zhongqi Liu,Fan Liu,Haixuan Wu,Xiaoyan Huang,Rong Huang,Phei Er Saw,Minghui Cao

DOI: https://doi.org/10.2147/ijn.s453608

IF: 7.033

2024-05-28

International Journal of Nanomedicine

Abstract:Hongmei Yang, 1, &ast Zhongqi Liu, 1, &ast Fan Liu, 1, 2, &ast Haixuan Wu, 1 Xiaoyan Huang, 1 Rong Huang, 1 Phei Er Saw, 3, 4 Minghui Cao 1, 2 1 Department of Anesthesiology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, People's Republic of China; 2 Department of Anesthesiology, Shenshan Medical Center, Sun Yat-Sen Memorial Hospital, Sun Yat-sen University, Shanwei, 516600, People's Republic of China; 3 Medical Research Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, People's Republic of China; 4 Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, People's Republic of China &astThese authors contributed equally to this work Correspondence: Phei Er Saw; Minghui Cao, Email ; Background: Opioids are irreplaceable analgesics owing to the lack of alternative analgesics that offer opioid-like pain relief. However, opioids have many undesirable central side effects. Restricting opioids to peripheral opioid receptors could reduce those effects while maintaining analgesia. Methods: To achieve this goal, we developed Tet1-LNP (morphine), a neural-targeting lipid nanoparticle encapsulating morphine that could specifically activate the peripheral opioid receptor in the dorsal root ganglion (DRG) and significantly reduce the side effects caused by the activation of opioid receptors in the brain. Tet1-LNP (morphine) were successfully prepared using the thin-film hydration method. In vitro, Tet1-LNP (morphine) uptake was assessed in differentiated neuron-like PC-12 cells and dorsal root ganglion (DRG) primary cells. The uptake of Tet1-LNP (morphine) in the DRGs and the brain was assessed in vivo. Von Frey filament and Hargreaves tests were used to assess the antinociception of Tet1-LNP (morphine) in the chronic constriction injury (CCI) neuropathic pain model. Morphine concentration in blood and brain were evaluated using ELISA. Results: Tet1-LNP (morphine) had an average size of 131 nm. Tet1-LNP (morphine) showed high cellular uptake and targeted DRG in vitro. CCI mice treated with Tet1-LNP (morphine) experienced prolonged analgesia for nearly 32 h compared with 3 h with free morphine ( p < 0.0001). Notably, the brain morphine concentration in the Tet1-LNP (morphine) group was eight-fold lower than that in the morphine group ( p < 0.0001). Conclusion: Our study presents a targeted lipid nanoparticle system for peripheral neural delivery of morphine. We anticipate Tet1-LNP (morphine) will offer a safe formulation for chronic neuropathic pain treatment, and promise further development for clinical applications. Keywords: lipid nanoparticle, Tet1, peripheral nerve-targeted, pain management, chronic neuropathic pain Opioids remain the mainstay of analgesic treatment for perioperative, severe, acute, and chronic pain. However, opioid clinical effectiveness is restricted due to adverse side effects that are mainly caused by activating the μ-opioid receptors in the central nervous system (CNS), 1 including sedation, apnea, tolerance, and addiction which lead to an epidemic of overdoses, death, and abuse. 2 Therefore, there is an urgent need to develop novel therapeutic strategies for the management of pain. Currently, various approaches are being explored, including focusing on μ-opioid receptor (MOR) splice variants, generating biased agonists, or targeting other receptors such as heteromers with MOR. 3 Despite significant advances, clinical translation of these strategies remains challenging. Researchers have reduced opioid side effects by regulating transient receptor potential vanilloid 1 (TRPV1) receptors. 4 However, TRPV1 antagonists may increase the thermal pain threshold in humans, potentially increasing the risk of burn injury. 5 As central effects account for the majority of opioid-related adverse effects, the use of opioid receptors only in peripheral sensory neurons is a promising therapeutic strategy to limit central adverse effects while maintaining analgesic effects. 3 There is growing evidence that peripheral sensory neurons mediate antinociceptive effects. 6,7 Primary sensory neurons, with cell bodies within dorsal root ganglia (DRGs), project fibers to the peripheral terminals of sensory neurons 8 and opioid receptors exist in DRG neurons of different diameters and prototypical sensory neuropeptides. 9 When there is a pain signal, opioid recep -Abstract Truncated-

pharmacology & pharmacy,nanoscience & nanotechnology
The impact of multifunctional enkephalin analogs and morphine on the protein changes in crude membrane fractions isolated from the rat brain cortex and hippocampus

Hana Ujcikova,Yeon Sun Lee,Lenka Roubalova,Petr Svoboda

DOI: https://doi.org/10.1016/j.peptides.2024.171165

IF: 3.867

2024-02-03

Peptides

Abstract:Endogenous opioid peptides serve as potent analgesics through the opioid receptor (OR) activation. However, they often suffer from poor metabolic stability, low lipophilicity, and low blood-brain barrier permeability. Researchers have developed many strategies to overcome the drawbacks of current pain medications and unwanted biological effects produced by the interaction with opioid receptors. Here, we tested multifunctional enkephalin analogs LYS739 (MOR/DOR agonist and KOR partial antagonist) and LYS744 (MOR/DOR agonist and KOR full antagonist) under in vivo conditions in comparison with MOR agonist, morphine. We applied 2D electrophoretic resolution to investigate differences in proteome profiles of crude membrane (CM) fractions isolated from the rat brain cortex and hippocampus exposed to the drugs (10 mg/kg, seven days). Our results have shown that treatment with analog LYS739 induced the most protein changes in cortical and hippocampal samples. The identified proteins were mainly associated with energy metabolism, cell shape and movement, apoptosis, protein folding, regulation of redox homeostasis, and signal transduction. Among these, the isoform of mitochondrial ATP synthase subunit beta (ATP5F1B) was the only protein upregulation in the hippocampus but not in the brain cortex. Contrarily, the administration of analog LYS744 caused a small number of protein alterations in both brain parts. Our results indicate that the KOR full antagonism, together with MOR/DOR agonism of multifunctional opioid ligands, can be beneficial in treating chronic pain states by reducing changes in protein expression levels but retaining analgesic efficacy.

pharmacology & pharmacy,biochemistry & molecular biology,endocrinology & metabolism
Morphine-responsive neurons that regulate mechanical antinociception

Michael P. Fatt,Ming-Dong Zhang,Jussi Kupari,Müge Altınkök,Yunting Yang,Yizhou Hu,Per Svenningsson,Patrik Ernfors

DOI: https://doi.org/10.1126/science.ado6593

IF: 56.9

2024-09-01

Science

Abstract:Opioids are widely used, effective analgesics to manage severe acute and chronic pain, although they have recently come under scrutiny because of epidemic levels of abuse. While these compounds act on numerous central and peripheral pain pathways, the neuroanatomical substrate for opioid analgesia is not fully understood. By means of single-cell transcriptomics and manipulation of morphine-responsive neurons, we have identified an ensemble of neurons in the rostral ventromedial medulla (RVM) that regulates mechanical nociception in mice. Among these, forced activation or silencing of excitatory RVM BDNF projection neurons mimicked or completely reversed morphine-induced mechanical antinociception, respectively, via a brain-derived neurotrophic factor (BDNF)/tropomyosin receptor kinase B (TrkB)–dependent mechanism and activation of inhibitory spinal galanin-positive neurons. Our results reveal a specific RVM-spinal circuit that scales mechanical nociception whose function confers the antinociceptive properties of morphine.

multidisciplinary sciences
Spinal Administration of the Multi-Functional Opioid/neuropeptide FF Agonist BN-9 Produced Potent Antinociception Without Development of Tolerance and Opioid-Induced Hyperalgesia.

Run Zhang,Biao Xu,Qinqin Zhang,Dan Chen,Mengna Zhang,Guanghai Zhao,Kangtai Xu,Jian Xiao,Hanwen Zhu,Jiandong Niu,Ning Li,Quan Fang

DOI: https://doi.org/10.1016/j.ejphar.2020.173169

IF: 5.195

2020-01-01

European Journal of Pharmacology

Abstract:Chronic opioids treatment is impeded by the development of analgesic tolerance and opioid-induced hyperalgesia. Recent studies have shown that multi-functional opioid compounds produce analgesic activities with limited side effects. We developed a novel multi-functional peptide targeting opioid and neuropeptide FF receptors named BN-9, which produced potent and non-tolerance forming antinociceptive effect after supraspinal and systemic administrations. In the present study, the analgesic properties and potential side effects of intrathecal BN-9 were investigated in a range of preclinical rodent models. In complete Freund's adjuvant-induced inflammatory pain model, intrathecal BN-9 dose-dependently produced analgesic effect via opioid receptors, and the spinal antinociceptive effect was augmented by the neuropeptide FF receptor antagonist RF9. In contrast, in plantar incision-induced postoperative pain model, BN-9 exhibited potent anti-allodynic effect via opioid receptors and, at least partially, neuropeptide FF receptors. In mouse models of acetic acid-induced visceral pain and formalin pain, BN-9-induced spinal antinociception was mainly mediated by opioid receptors, independent of neuropeptide FF receptors. Furthermore, at the spinal level, chronic treatments with BN-9 did not lead to analgesic tolerance and cross-tolerance to morphine. Moreover, opioid-induced hyperalgesia was observed after repeated administration of morphine, but not BN-9. Taken together, our present study suggests that intrathecal BN-9 produces potent and non-tolerance forming antinociception, and does not cause opioid-induced hyperalgesia. Thus, BN-9 might serve as a promising lead compound in the development of multi-functional opioid analgesics with minimized side effects.
Peripheral Administration of an Opioid Peptide Analog Ameliorates Morphine-Produced Hyperalgesia in a Spared Nerve Injury Model

Wang Yuan,Shijiazhuang People’s Hospital,Wang Jing,Han Chao-zhen-yi,Li Kai,Ru Qiao-min,Li Na,Liu Xin,Wang Rui

DOI: https://doi.org/10.1007/s10989-021-10319-4

2021-01-01

International Journal of Peptide Research and Therapeutics

Abstract:Traditional opioids have proven analgesic effects in clinical applications but are also associated with side effects, especially hyperalgesia. Reducing the occurrence of hyperalgesia is part of effective clinical pain management. In this study, we investigated the difference between MEL-0614, a novel endomorphin analog that can effectively penetrate the blood–brain barrier, and morphine in inducing hyperalgesia. Under mechanical and thermal stimulation conditions, intravenous administration of morphine led to hyperalgesia even at low concentrations, which was not observed with MEL-0614 even at high concentrations. In a spared nerve injury model, significantly less aggravation of allodynia was caused by an intravenous injection of MEL-0614 compared with that caused by morphine, and the allodynia symptoms occurred later. Notably, MEL-0614 significantly relieved the symptoms of morphine-induced allodynia. The activation of N-methyl-d-aspartic acid receptor and expression of inflammatory mediators differed in spinal microglia after intravenous injections of MEL-0614 and morphine. Intravenous injections of morphine induced increases in the number of microglia and overexpression of inflammatory factors, including tumor necrotic factor and interleukin-1β. Conversely, the effects of MEL-0614 administration did not differ from those of saline, and there was no inflammatory mediator overexpression. Especially in the spared nerve injury model, the cross-administration of morphine and MEL-0614 could reduce the expression of Toll-like receptor 4 and other related genes to different degrees compared with the use of morphine alone. Concurrently, the results could also explain the alleviating effect of MEL-0614 on morphine-induced pain sensitivity in behavioral experiments. Our findings may provide important information regarding the clinical treatment of neuropathic pain in the future.
MP-13, a novel chimeric peptide of morphiceptin and pepcan-9, produces potent antinociception with limited side effects

Chenxi Mei,Jing Zhang,Zhanyu Niu,Jerine Peter Simon,Tong Yang,Mingmin Huang,Zhonghua Zhang,Lanxia Zhou,Shouliang Dong

DOI: https://doi.org/10.1016/j.npep.2024.102440

IF: 3.152

2024-06-10

Neuropeptides

Abstract:Pharmacological investigations have substantiated the potential of bifunctional opioid/cannabinoid agonists in delivering potent analgesia while minimizing adverse reactions. Peptide modulators of cannabinoid receptors, known as pepcans, have been investigated before. In this study, we designed a series of chimeric peptides based on pepcans and morphiceptin (YPFP-NH2). Here, we combined injections of pepcans and morphiceptin to investigate the combination treatment of opioids and cannabis and compared the analgesic effect with chimeric compounds. Subsequently, we employed computational docking to screen the compounds against opioid and cannabinoid receptors, along with an acute pain model, to identify the most promising peptide. Among these peptides, MP-13, a morphiceptin and pepcan-9 (PVNFKLLSH) construct, exhibited superior supraspinal analgesic efficacy in the tail-flick test, with an ED50 value at 1.43 nmol/mouse, outperforming its parent peptides and other chimeric analogs. Additionally, MP-13 displayed potent analgesic activity mediated by mu-opioid receptor (MOR), delta-opioid receptor (DOR), and cannabinoid type 1 (CB1) receptor pathways. Furthermore, MP-13 did not induce psychological dependence and gastrointestinal motility inhibition at the effective analgesic doses, and it maintained non-tolerance-forming antinociception throughout a 7-day treatment regimen, with an unaltered count of microglial cells in the periaqueductal gray region, supporting this observation. Moreover, intracerebroventricular administration of MP-13 demonstrated dose-dependent antinociception in murine models of neuropathic, inflammatory, and visceral pain. Our findings provide promising insights for the development of opioid/cannabinoid peptide agonists, addressing a crucial gap in the field and holding significant potential for future research and development. PERSPECTIVE: This article offers insights into the combination treatment of pepcans with morphiceptin. Among the chimeric peptides, MP-13 exhibited potent analgesic effects in a series of preclinical pain models with a favorable side-effect profile.
Antinociceptive Efficacy of the µ-Opioid/Nociceptin Peptide-Based Hybrid KGNOP1 in Inflammatory Pain without Rewarding Effects in Mice: An Experimental Assessment and Molecular Docking

Maria Dumitrascuta,Marcel Bermudez,Olga Trovato,Jolien De Neve,Steven Ballet,Gerhard Wolber,Mariana Spetea

DOI: https://doi.org/10.3390/molecules26113267

IF: 4.6

2021-05-28

Molecules

Abstract:Opioids are the most effective analgesics, with most clinically available opioids being agonists to the µ-opioid receptor (MOR). The MOR is also responsible for their unwanted effects, including reward and opioid misuse leading to the current public health crisis. The imperative need for safer, non-addictive pain therapies drives the search for novel leads and new treatment strategies. In this study, the recently discovered MOR/nociceptin (NOP) receptor peptide hybrid KGNOP1 (H-Dmt-D-Arg-Aba-β-Ala-Arg-Tyr-Tyr-Arg-Ile-Lys-NH2) was evaluated following subcutaneous administration in mouse models of acute (formalin test) and chronic inflammatory pain (Complete Freund's adjuvant-induced paw hyperalgesia), liabilities of spontaneous locomotion, conditioned place preference, and the withdrawal syndrome. KGNOP1 demonstrated dose-dependent antinociceptive effects in the formalin test, and efficacy in attenuating thermal hyperalgesia with prolonged duration of action. Antinociceptive effects of KGNOP1 were reversed by naltrexone and SB-612111, indicating the involvement of both MOR and NOP receptor agonism. In comparison with morphine, KGNOP1 was more potent and effective in mouse models of inflammatory pain. Unlike morphine, KGNOP1 displayed reduced detrimental liabilities, as no locomotor impairment nor rewarding and withdrawal effects were observed. Docking of KGNOP1 to the MOR and NOP receptors and subsequent 3D interaction pattern analyses provided valuable insights into its binding mode. The mixed MOR/NOP receptor peptide KGNOP1 holds promise in the effort to develop new analgesics for the treatment of various pain states with fewer MOR-mediated side effects, particularly abuse and dependence liabilities.
Antioxidant Cascade Nanoenzyme Antagonize Inflammatory Pain by Modulating MAPK/p-65 Signaling Pathway

Yuejuan Ling,Dekang Nie,Yue Huang,Mengyuan Deng,Qianqian Liu,Jinlong Shi,Siguang Ouyang,Yu Yang,Song Deng,Zhichao Lu,Junling Yang,Yi Wang,Rongqin Huang,Wei Shi

DOI: https://doi.org/10.1002/advs.202206934

2023-01-01

Abstract:Chronic pain has attracted wide interest because it is a major obstacle affecting the quality of life. Consequently, safe, efficient, and low-addictive drugs are highly desirable. Nanoparticles (NPs) with robust anti-oxidative stress and anti-inflammatory properties possess therapeutic possibilities for inflammatory pain. Herein, a bioactive zeolitic imidazolate framework (ZIF)-8-capped superoxide dismutase (SOD) and Fe3O4 NPs (SOD&Fe3O4@ZIF-8, SFZ) is developed to achieve enhanced catalytic, antioxidative activities, and inflammatory environment selectivity, ultimately improving analgesic efficacy. SFZ NPs reduce tert-butyl hydroperoxide (t-BOOH)-induced reactive oxygen species (ROS) overproduction, thereby depressing the oxidative stress and inhibiting the lipopolysaccharide (LPS)-induced inflammatory response in microglia. After intrathecal injection, SFZ NPs efficiently accumulate at the lumbar enlargement of the spinal cord and significantly relieve complete Freund's adjuvant (CFA)-induced inflammatory pain in mice. Moreover, the detailed mechanism of inflammatory pain therapy via SFZ NPs is further studied, where SFZ NPs inhibit the activation of the mitogen-activated protein kinase (MAPK)/p-65 signaling pathway, leading to reductions in phosphorylated protein levels (p-65, p-ERK, p-JNK, and p-p38) and inflammatory factors (tumor necrosis factor [TNF]-alpha, interleukin [IL]-6, and IL-1 beta), thereby preventing microglia and astrocyte activation for acesodyne. This study provides a new cascade nanoenzyme for antioxidant treatments and explores its potential applications as non-opioid analgesics.
Comparison of Morphine and Endomorphin Analog ZH853 for Tolerance and Immunomodulation in a Rat Model of Neuropathic Pain

Terrence J Hunter,Zoe M Videlefsky,Leticia Ferreira Nakatani,James E Zadina

DOI: https://doi.org/10.1016/j.jpain.2024.104607

Abstract:µ-Opioid receptor agonists, the gold standard for analgesia, come with significant side effects when used chronically. Tolerance, defined as the decrease in analgesic activity after repeated use, remains a vital therapeutic obstacle as it increases the likelihood of dose escalation and potentially lethal side effects like respiratory depression. Previous experiments have shown that the endomorphin-1 analog, ZH853, is a specific µ-opioid receptor agonist with reduced side effects like tolerance and glial activation following chronic central administration in pain-naive animals. Here, we investigated the effects of chronic, peripheral administration of µ-opioid receptor agonists following neuropathic injury. Though µ-opioids are effective at reducing neuropathic pain, they are not recommended for first-line treatment due to negative side effects. Compared with chronic morphine, chronic ZH853 treatment led to decreased tolerance and reduced glial activation. Following twice-daily intravenous injections, morphine was less potent and had a shorter duration of antinociception compared with ZH853. Chronic morphine, but not chronic ZH853, elevated markers of activation/inflammation of astrocytes (glial fibrillary acidic protein), microglia (ionized calcium-binding adapter molecule 1), the proinflammatory cytokine tumor necrosis factor-α, and phosphorylated mitogen-activated protein (MAP) kinase p38 (pp38). By contrast, chronic ZH853 reduced ionized calcium-binding adapter molecule 1 and tumor necrosis factor-α relative to both morphine and vehicle, suggesting anti-inflammatory properties with respect to these markers. Glial fibrillary acidic protein and pp38 were not significantly different from vehicle but were significantly lower than morphine. This study demonstrates the effectiveness of chronic ZH853 for providing analgesia in a neuropathic pain state with reduced tolerance compared with morphine, potentially due to reductions in spinal glial activation. PERSPECTIVE: Neuropathic pain is generally undertreated and resistant to medication, and side-effects limit opioid treatment. Here, we show that, compared with an equiantinociceptive dose of morphine, chronic intravenous administration of endomorphin analog ZH853 led to prolonged antiallodynia, reduced tolerance, and inhibition of spinal cord neuroinflammation in male spared nerve-injured rats.
In Vitro and In Vivo Pharmacological Profiles of LENART01, a Dermorphin–Ranatensin Hybrid Peptide

Nadine Hochrainer,Pawel Serafin,Sara D’Ingiullo,Adriano Mollica,Sebastian Granica,Marek Brytan,Patrycja Kleczkowska,Mariana Spetea

DOI: https://doi.org/10.3390/ijms25074007

IF: 5.6

2024-04-04

International Journal of Molecular Sciences

Abstract:Diverse chemical and pharmacological strategies are currently being explored to minimize the unwanted side effects of currently used opioid analgesics while achieving effective pain relief. The use of multitarget ligands with activity at more than one receptor represents a promising therapeutic approach. We recently reported a bifunctional peptide-based hybrid LENART01 combining dermorphin and ranatensin pharmacophores, which displays activity to the mu-opioid receptor (MOR) and dopamine D2 receptor (D2R) in rat brains and spinal cords. In this study, we investigated the in vitro binding and functional activities to the human MOR and the in vivo pharmacology of LENART01 in mice after subcutaneous administration. In vitro binding assays showed LENART01 to bind and be selective to the human MOR over the other opioid receptor subtypes and delta, kappa and nociceptin receptors. In the [35S]GTPγS binding assay, LENART01 acted as a potent and full agonist to the human MOR. In mice, LENART01 produced dose-dependent antinociceptive effects in formalin-induced inflammatory pain, with increased potency than morphine. Antinociceptive effects were reversed by naloxone, indicating MOR activation in vivo. Behavioral studies also demonstrated LENART01's properties to induce less adverse effects without locomotor dysfunction and withdrawal syndrome compared to conventional opioid analgesics, such as morphine. LENART01 is the first peptide-based MOR-D2R ligand known to date and the first dual MOR-dopamine D2R ligand for which in vivo pharmacology is reported with antinociceptive efficacy and reduced opioid-related side effects. Our current findings may pave the way to new pain therapeutics with limited side effects in acute and chronic use.

biochemistry & molecular biology,chemistry, multidisciplinary
Design and Synthesis of a Novel Series of Opioid Dipeptides and Evaluation of Their Analgesic Effect in Vivo

Liu Xin,Zhao Long,Wang Yuan,Mou Lingyun,Zhang Yixin,Zhou Jingjing,Wang Rui

DOI: https://doi.org/10.6023/a15090611

2016-01-01

Acta Chimica Sinica

Abstract:The opioid system is one of the most studied pain relieving systems. Opioid peptides have been studied extensively since their discovery, and many efforts have been dedicated to the determination of their intrinsic nature. However, opioid peptides still suffer from serious limitations including lack of oral activity, short duration of action, poor metabolic stability, and relative inability to cross the blood-brain barrier (BBB). Inspired by the structure-activity studies of opioid peptides, four novel opioid dipeptides were synthesized by introduction of Tyr/Dmt to the N-termius and novel unnatural alpha-methylene-beta-amino acids (Map) to the C-terminus. Their in vitro and in vivo activities were determined and compared. The affinity and selectivity of these dipeptides were evaluated by radioligand binding assay in whole cell preparations from HEK293 cells expressing the delta opioid receptor (MOR) or d opioid receptor (DOR), compound 4 exhibited the highest binding affinity toward MOR, and this compound also showed the most significant MOR selectivity over DOR. Pharmacological activities were evaluated in vitro using isolated guinea pig ileum (GPI) for MOR and mouse vas deferens (MVD) for DOR, and the results of GPI and MVD were in accordance with the binding affinity assays. The antinociceptive activities of the compound 4 were assessed in the mouse tail-flick and writhing test after intracerebroventricular (i.c.v.) administration. In the two tests, compound 4 showed good ability to reduce the thermal pain and the inflammatory pain, respectively. Naloxone significantly reversed the activity of the compound, indicating that opioid receptors were involved in its analgesic effects. The compound 4 was then administered inravenously (i.v.) to determine whether this dipeptide was able to cross the BBB. As a result, compound 4 was effective in both tail-flick and writhing test after i.v. administration. Furthermore, the peripherally restricted opioid antagonist naloxone methiodide did not alter the peptide-induced antinociception. Collectively, these results indicated that compound 4 was able to cross the highly selective BBB and might elicit an analgesic response via a central mechanism. Therefore, compound 4 may be a potential lead compound for future clinical development for pain management.
Endomorphin-1 Analogues (mels) Penetrate the Blood–brain Barrier and Exhibit Good Analgesic Effects with Minimal Side Effects

Yuan Wang,Xin Liu,Dan Wang,Junxian Yang,Long Zhao,Jing Yu,Rui Wang

DOI: https://doi.org/10.1016/j.neuropharm.2015.06.010

IF: 5.273

2015-01-01

Neuropharmacology

Abstract:Endomorphins are endogenous opioid peptides in mammals and display a strong antinociceptive effect after central administration. However, the clinical usage of these peptides is limited because of their diminished analgesic effect following systemic injection and their inability to cross the blood−brain barrier. In this study, we characterized the in vivo effects of four novel endomorphin-1 analogues (termed MELs), which previously showed potential as highly potent analgesics with a good pharmacological profile in vitro. The analogues were administered intravenously to several rodent pain models to examine their antinociception and blood−brain barrier permeability. The tested peptides, especially MEL1214, showed good analgesic activity and blood−brain barrier permeability. Behavioral studies showed dose-dependent analgesic effect after systematic administration of MEL1214 in the tested pain models. Pre-treatment of subcutaneous administration of naloxone methiodide did not affect the antinociception of these peptides. As compared to morphine, MEL1214 was less prone to induce tolerance after consecutive intravenous administration for 5 days. Gastrointestinal transit was evaluated by the isolated colon response and bead expulsion to determine the potential constipation effect. In contrast to morphine, MEL1214 produced no significant constipation effect at an equivalent dose. MEL1214 shows promise as a suitable compound to treat pain with reduced side effects, and exhibits good potential to be further developed as a novel opioid analgesic in pain treatment.
MEL-N16: A Series of Novel Endomorphin Analogs with Good Analgesic Activity and a Favorable Side Effect Profile

Xin Liu,Long Zhao,Yuan Wang,Jingjing Zhou,Dan Wang,Yixin Zhang,Xianghui Zhang,Zhaojuan Wang,Dongxu Yang,Lingyun Mou,Rui Wang

DOI: https://doi.org/10.1021/acschemneuro.7b00097

2017-10-18

Abstract:Opioid peptides are neuromodulators that bind to opioid receptors and reduce pain sensitivity. Endomorphins are among the most active endogenous opioid peptides, and they have good affinity and selectivity toward the μ opioid receptor. However, their clinical usage is hindered by their inability to cross the blood-brain barrier and their poor in vivo activity after peripheral injection. In order to overcome these defects, we have designed and synthesized a series of novel endomorphin analogs with multiple site modifications. Radioligand binding, cAMP accumulation, and β-arrestin-2 recruitment assays were employed to determine the activity of synthesized endomorphin analogs toward opioid receptors. The blood-brain barrier permeability and antinociceptive effect of these analogs were determined in several rodent models of acute and persistent pain. In addition, the side effects of the analogs were examined. The radioligand binding assay and functional activity examination indicated that the MEL-N16 series of compounds were more active agonists against μ opioid receptor than were the parent peptides. Notably, the analogs displayed biased downstream signaling toward G-protein pathways over β-arrestin-2 recruitment. The analogs showed highly potent antinociceptive effects in the tested nociceptive models. In comparison with endomorphins, the synthesized analogs were better able to penetrate the blood-brain barrier and exerted their pain regulatory activity in the central nervous system after peripheral injection. These analogs also have lower tendency to cause side effects than morphine does at similar or equal antinociceptive doses. The MEL-N16 compounds have highly potent and efficacious analgesic effects in various pain models with a favorable side effect profile.

A new painkiller nanomedicine to bypass the blood-brain barrier and the use of morphine

Mesoporous Silica Particles As a Multifunctional Delivery System for Pain Relief in Experimental Neuropathy.

Design, Synthesis, and Biological Evaluation of the Third Generation 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan (NAP) Derivatives As Μ/κ Opioid Receptor Dual Selective Ligands.

A Synthetic Peptide Exerts Nontolerance-Forming Antihyperalgesic and Antidepressant Effects in Mice

Pain relief devoid of opioid side effects following central action of a silylated neurotensin analog

Intrinsic anti-inflammatory nanomedicines for enhanced pain management

Analgesic Nanomedicines for the Treatment of Chronic Pain

Building a better analgesic: multifunctional compounds that address injury-induced pathology to enhance analgesic efficacy while eliminating unwanted side effects

TET1-Lipid Nanoparticle Encapsulating Morphine for Specific Targeting of Peripheral Nerve for Pain Alleviation

The impact of multifunctional enkephalin analogs and morphine on the protein changes in crude membrane fractions isolated from the rat brain cortex and hippocampus

Morphine-responsive neurons that regulate mechanical antinociception

Spinal Administration of the Multi-Functional Opioid/neuropeptide FF Agonist BN-9 Produced Potent Antinociception Without Development of Tolerance and Opioid-Induced Hyperalgesia.

Peripheral Administration of an Opioid Peptide Analog Ameliorates Morphine-Produced Hyperalgesia in a Spared Nerve Injury Model

MP-13, a novel chimeric peptide of morphiceptin and pepcan-9, produces potent antinociception with limited side effects

Antinociceptive Efficacy of the µ-Opioid/Nociceptin Peptide-Based Hybrid KGNOP1 in Inflammatory Pain without Rewarding Effects in Mice: An Experimental Assessment and Molecular Docking

Antioxidant Cascade Nanoenzyme Antagonize Inflammatory Pain by Modulating MAPK/p-65 Signaling Pathway

Comparison of Morphine and Endomorphin Analog ZH853 for Tolerance and Immunomodulation in a Rat Model of Neuropathic Pain

In Vitro and In Vivo Pharmacological Profiles of LENART01, a Dermorphin–Ranatensin Hybrid Peptide

Design and Synthesis of a Novel Series of Opioid Dipeptides and Evaluation of Their Analgesic Effect in Vivo

Endomorphin-1 Analogues (mels) Penetrate the Blood–brain Barrier and Exhibit Good Analgesic Effects with Minimal Side Effects

MEL-N16: A Series of Novel Endomorphin Analogs with Good Analgesic Activity and a Favorable Side Effect Profile